From the Research
Oral semaglutide (Rybelsus) is the only available oral GLP-1 receptor agonist, which is a GLP-1 analog formulated with an absorption enhancer (SNAC) that allows the peptide to be absorbed through the stomach lining. This medication has been shown to be effective in improving glycemic control, reducing body weight, and decreasing systolic blood pressure in patients with type 2 diabetes 1. The PIONEER 6 trial demonstrated the cardiovascular safety of oral semaglutide, with a significant reduction in cardiovascular and overall mortality 2. Oral semaglutide may be an attractive option for patients with type 2 diabetes who require improved glycemic control, would like to lose weight, and who are not interested in injectable therapy 3.
Some key points to consider when prescribing oral semaglutide include:
- It is indicated for use as an add-on combination therapy or as a monotherapy for type 2 diabetes when diet and exercise do not provide adequate glycemic control 1
- It has a safety profile consistent with the GLP-1RA drug class, with a low risk of hypoglycemia and common adverse events being gastrointestinal 1
- It has been shown to be effective in patients with type 2 diabetes at various stages, including those who are intolerant to metformin 4
- It may be particularly suitable for the treatment of the initial phase of type 2 diabetes, but it is also effective at later initiation of therapy, in different diabetic populations 2
Overall, oral semaglutide is a valuable treatment option for patients with type 2 diabetes, offering improved glycemic control, weight loss, and cardiovascular safety. However, it is essential to carefully evaluate the individual patient's needs and consider the potential benefits and limitations of oral semaglutide in the context of their overall treatment plan.